Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer
Conversion from accelerated to regular (full) approval based on long-term outcomes from the GARNET phase I trial
US FDA Advisory Committee votes in support of trials designed to evaluate Jemperli (dostarlimab-gxly) as a potential treatment for mismatch repair-deficient/microsatellite instability-high locally advanced rectal cancer
In January 2023, the US FDA granted dostarlimab-gxly Fast Track designation for the treatment of dMMR/MSI-H locally advanced rectal cancer.
GSK announces results from 17-year retrospective study on US clinical trial diversity
Study examined clinical trial diversity across 495 GSK trials involving over 100,000 participants.
Jesduvroq (daprodustat) approved by US FDA for anaemia of chronic kidney disease in adults on dialysis
Jesduvroq is the only oral HIF-PHI approved in the US, offering adults on dialysis with anaemia of CKD a new oral treatment option
GSK delivers strong 2022 performance with full year sales of £29.3 billion +19% AER, +13% CER; Total EPS 371.4p >100% Adjusted EPS of 139.7p +27% AER, +15% CER from continuing operations
Step change in commercial execution drives strong sales growth across Specialty Medicines and Vaccines
Benlysta granted Orphan Drug Designation by US FDA for the potential treatment of systemic sclerosis
GSK plans to initiate a phase II/III trial for systemic sclerosis associated interstitial lung disease (SSc-ILD) in the first half of 2023.
VidPrevtyn Beta COVID-19 booster vaccine, developed by Sanofi and GSK, approved for use in Great Britain
SARS-CoV-2 spike protein vaccine is the first and only protein-based variant COVID-19 booster vaccine approved in Great Britain and the EU
GSK and Wave Life Sciences announce collaboration to drive discovery and development of oligonucleotide therapeutics focusing on novel genetic targets
A strategic collaboration to advance oligonucleotide therapeutics, including Wave’s preclinical RNA editing programme
GSK announces new global headquarters in central London
GSK today announced that its new global headquarters will be in central London. The company will move to the new headquarters in 2024.
New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients
GSK today announced new 48-week data from the MOMENTUM phase III trial...
PERLA phase II trial of Jemperli (dostarlimab) plus chemotherapy shows positive results in first-line metastatic non-squamous non-small cell lung cancer
PERLA is the largest global head-to-head trial of PD-1 inhibitors in this patient population
Statement: Zantac (ranitidine) litigation
MDL Court has dismissed all cases alleging the five remaining cancers in the MDL
Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer
Regulatory submissions based on the trial results are planned for the first half of 2023.
European Medicines Agency accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis
Application includes data from key phase III trials, including the pivotal MOMENTUM trial.
New global survey reveals opportunities to address organ damage risk with people living with lupus earlier in the course of their disease
Survey examined healthcare professional approaches to preventing organ damage
GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisation
GSK has initiated the process for withdrawal of the US marketing authorisation for Blenrep (belantamab mafodotin-blmf)
GSK tops Access to Medicine Index (ATMI) for eighth consecutive time
Company also announces £100 million investment over next ten years to support access initiatives in lower income countries
GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis
Results demonstrate the potential for this asset to be a component of simpler TB treatment regimens in the future.
GSK provides an update on Zejula (niraparib) US prescribing information
Zejula is an oral, once-daily PARP inhibitor currently being evaluated in multiple pivotal trials.